Post de adMare BioInnovations

📢 IRICoR congratulates CQDM on the launch of CELLULE IRICoR is proud to congratulate CQDM and its partners - AReNA, Axelys, Fonds de recherche du Québec, Génome Québec, and Médicament Québec - on the groundbreaking launch of the CELLULE initiative. Announced at the prestigious BIO International Convention, this new model aims to accelerate the development of RNA therapies in Quebec, positioning the region as a global leader in this innovative field. 🔬 This initiative, backed by a world-class industrial advisory committee, will launch several calls for solutions, inviting technological innovations from Quebec’s academic and industrial communities. Projects demonstrating commercial value could receive ongoing funding, ensuring their progress from concept to market. IRICoR fully supports this visionary initiative, recognizing its potential to overcome challenges in RNA-based therapy applications and drive significant growth in Quebec’s life sciences sector. The collaborative effort embodied by the CELLULE will undoubtedly lead to the emergence of new technologies, enhancing Quebec’s position on the global stage. We look forward to seeing the transformative impact of the CELLULE on healthcare and the broader society. #CQDM #Innovation #Healthcare #RNA #Research #Collaboration #Lifesciences #BIO2024 #CELLULE #Biotech #Pharma #Leadership #BusinessExcellence #ScientificDiscovery

The FDA Orphan Drug designation incentive has facilitated the development of innovative treatments for rare diseases. In that context, we are pleased to announce our collaboration with the FONDATION SANFILIPPO SUISSE, to further accelerate the discovery and approval of treatment against Mucopolysaccharidosis (#mps).   The Swiss Data Science Center has been applying state-of-the-art artificial intelligence methods on public databases with the aim of repositioning already commercially available drugs for the treatment of MPS. This project will allow an in-depth exploration of innovative treatment options and significantly reduce drug development time, towards patient recovery. By leveraging cutting-edge #datascience techniques, we are empowering #biomedical organizations to embark on a transformative journey toward more data-driven and integrative health solutions. Olivier Verscheure, Silvia Quarteroni, Matthias Galipaud, Lucas Chizzali, Anna Fournier, PhD, Nicolas Lantz, Ph.D. #orphandrugs #rarediseaseresearch #drugdevelopment Photo of Hugo, courtesy of the Swiss #sanfilippo Foundation.  

The potential of cyclodextrins in addressing age-related issues, particularly in longevity and heart health, is a promising area of research. Cyclodextrins, cyclic oligosaccharides, have shown potential in various biomedical applications, including drug delivery and cholesterol management. Matthew "Oki" O'Connor, CEO of Cyclarity Therapeutics, is exploring the impact of cholesterol on aging and the potential of cyclodextrins to address age-related issues. O'Connor's work is shedding light on the role of cholesterol in aging and the potential of cyclodextrins to improve healthspan and extend lifespan. Join us at Longevity Summit Dublin from June 13-16, 2024, to learn more about the latest developments in this field and connect with leading researchers, investors, and industry professionals. The summit will feature talks and networking opportunities, allowing attendees to learn about the latest developments and connect with experts in the field.   June 13-16, 2024 Dublin, Ireland Reserve your tickets at https://lnkd.in/dfbxP2Jy #Cyclodextrins #Longevity #AntiAging #Healthspan #Cholesterol #CyclarityTherapeutics #LongevitySummitDublin #levfoundation Matthew "Oki" O'Connor Aubrey de Grey Longevity Escape Velocity (LEV) Foundation Martin O 'Dea

Advanced Therapies Summit will be unleashing the potential of the Belgian ATMP sector on 19 October in Leuven, Belgium! Belgium is widely recognized as having a rich and dynamic ATMP sector, possessing the key ingredients needed to become a global leader in the advanced therapies domain. But challenges remain, and collaboration is key to overcoming them. That is why this event will unite the ‘quadruple helix’ of stakeholders – academia, industry, government, and patients – to highlight hurdles, examine the experience of other European ATMP hubs, and assess how the gaps in the Belgian ecosystem can be addressed. Be a part of the progress – register for the event today: https://lnkd.in/ewZmGJUJ #ATMP #advancedtherapies #healthcare #healthcareinnovation

👀 Did you miss the roundtable "Catalonia Advanced Therapies Ecosystem: Building Europe’s Future in ATMPs" at #RESIEurope2024? You can watch the recording of the debate here 👇 ▶️ https://lnkd.in/dYUZ8Cq5 The panel discussion highlighted the key role Catalonia’s advanced therapies will play in innovation and clinical breakthroughs in Europe. As Robert Fabregat Fuentes (#Biocat's CEO) emphasized: Catalonia ranks 5th in Europe and 8th worldwide in participation in clinical trials of #ATMPs. Moreover, the #BioRegion stands out in the number of publications on advanced therapies. 🗣 Luis Pareras MD, PhD (Invivo Partners) pointed to the quality of Catalan research: "In the field of advanced therapies and synthetic #biology, we have some of the best scientists in Europe and the world." For the roundtable participants, the main challenges posed by advanced therapies include attracting qualified #talent and ensuring patients' access to therapies. 🗣 Fina Lladós Canela (Amgen España) highlighted the need to scale up therapy production and ensure patient access: "It makes no sense to invest and attract innovation if it does not reach patients." Similarly, Esteve Trias i Adroher (Leitat Technological Center) expressed that while Catalonia is strong at both the beginning and end of the chain, it is fundamental to 💬 "build this bridge between research and transfer." 🗣 For Silvia Martín Lluesma (Vall d'Hebron Institute of Oncology (VHIO)), what is crucial is that researchers, clinicians, and regulatory professionals work hand in hand in the development of advanced therapies. To address these and other challenges in advanced therapies, Antoni Matilla Dueñas (BIOINTAXIS) brought up the recent creation of the Advanced Therapies Network of Catalonia, coordinated by #Biocat. 👉 This network aims to promote #research, manufacturing, and development of #AdvancedTherapies to make them accessible to the public efficiently and sustainably. #RESIEUROPE #RESIBARCELONA #RESI #ATMPs #AdvancedTherapies Life Science Nation

#ASH23 Analysis 3: #Gilead (Kite) and #BMS presented real-world (RW) and clinical data updates in r/r LBCL. Celltelligence provides insights and context for key selected presentations. The following topics are covered below: • BMS presented: ◦ Final analysis of the Ph2 PILOT study (https://bit.ly/48djNSZ) evaluating #Breyanzi (#CD19 CAR-T) in transplant-ineligible (TI) patients in 2L LBCL ◦ Results from a multicenter real-world (RW) study of Breyanzi in r/r #LBCL conducted in the US • Gilead (Kite) reported results from a RW study assessing the impact of bridging therapy (BT) prior to #Yescarta (CD19 CAR-T) infusion in the outcomes of US patients with ≥3L LBCL Celltelligence provides insights and context for key selected presentations: https://bit.ly/CT-835750

C-Path's Cure Drug Repurposing Collaboratory, and the CURE ID team will be onsite at the International Drug Repurposing Conference 2024 (#iDR24): Bridging boundaries for Innovative Drug Repurposing this week where key leaders in drug repurposing will unite. Co-organized by REMEDi4ALL, Beacon for Rare Diseases and MeRIT, the conference showcases how patient communities, researchers, industry and health authorities can benefit from cutting-edge drug repurposing. The agenda follows three topical paths in parallel: · Cancer · Rare Disease · Methodologies Find out more about the speakers, location, details here: https://lnkd.in/eRtYcAmZ Smith Heavner, PhD, RN | Marco Schito | Heather Stone | Shira Strongin | Keyla Tumas #CPath #REMEDi4ALL #Beacon #MeRIT #drugrepurposing #patientadvocacy

💥💥 Great news: #Wallonia, the Service public de Wallonie and BioWin - The Health Cluster of Wallonia are releasing €81 million as part of an innovation partnership dedicated to #ATMPs (Advanced Therapy Medicinal Products).   In total, this funding could create more than 470 direct jobs and 1,200 indirect jobs over the next five years, and will naturally further strengthen Wallonia's incredible life sciences ecosystem. 🔬 Some of our participating companies are now involved in this collaborative project, including NOVADIP Biosciences S.A., QUALITY ASSISTANCE S.A., PDC*line Pharma, LiveDrop and Ncardia/Cellistic. Congrats for this approach!   🧪 We're obviously delighted with this initiative, because promoting collaborative innovation means we can capitalise on our strengths, consolidate our position on the international market, and also bring significantly improve our healthcare.   It's all positive! Let's continue to support the biotech and life sciences #ecosystem in Wallonia. It's a force to be reckoned with! 💪   Read the Trend article 👉 https://lnkd.in/eYzZMVyi   #lifesciences #pharma #biotechs #medtechs #innovation Gery Lefebvre Caroline THIELEN Sophie Sauvage Franssen Christina Anne VEREECKE Valentin TONNEL

#DrugResearch | 𝗛𝗼𝘄 𝗮 𝗦𝘂𝗰𝘁𝗶𝗼𝗻 𝗖𝘂𝗽 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗕𝗹𝗼𝗼𝗱𝘀𝘁𝗿𝗲𝗮𝗺 | Bringing innovative solutions to medical treatment, a team of researchers led by Professor Jean-Christophe Leroux at ETH Zürich, including Nevena Paunović and David Klein Cerrejon, have developed a unique transdermal drug delivery system - a suction cup designed to administer medications via the cheek's mucosal lining. The initiative is now pursued by their start-up Transire Bio, aiming to bring this advanced product to the healthcare market. Measuring around 10mm in diameter and 6mm in height, the suction cup serves as a gentler alternative to needles. Funded by the Hauser-Stiftung and the ETH Foundation Pioneer Fellowship Programme, the project depicts a promising shift in medication delivery, potentially alleviating millions from the fear and discomfort linked with injections. 👉 Learn more >> https://lnkd.in/exncnpJD 👉 Original publication >> https://lnkd.in/dAxQvaSr 🇨🇭 Follow #ScienceSwitzerland for the latest news and emerging trends on Swiss science, technology, education, and innovation >> www.swissinnovation.org Follow us >> Science-Switzerland #Science | #Education | #Research | #Innovation | #Healthcare

Are you ready for the French Society of Haematology Congress? Dare to be part amongst engaging discussions between leading industry and research experts about hot topics in the field of haematology and haemato-oncology. If you're attending, be sure to catch Dr. Emilie Klein's poster presentation on comparing a house-testing method vs. our QuantideX qPCR BCR-ABL IS kit for BCR-ABL monitoring for patients with chronic myeloid leukaemia. 📅 Thursday 28th March ⏰ 17:15 - 18:00 (Zone des posters) Title: P176 - Comparaison du kit QuantideX® qPCR BCR-ABL IS (Asuragen) avec une technique “maison” pour la quantification des transcrits majeurs BCR::ABL1 https://bit.ly/4aws3io